MERIDIAN — Entry into medical device markets
A flexible-electronics maker eyes medical devices
No to scaled commercial entry into medical devices, and no to a staged entry. Authorize about $5M of tests instead, against the $67M a first funding stage would cost, and revisit only if they move the answer.
Executive summary and recommendation
No to scaled commercial entry into medical devices. The business MERIDIAN can reach at the participation level the brief allows does not make money: about $165M of revenue by 2032 at an operating margin of -1.7%, against a business it already runs that earns 7.6%. It consumes $221M of cash across six years, never reaches an operating profit inside them, and returns a net present value of about -$99M.
Do not fund a staged entry either. Authorize about $5M of tests instead, run them before the 15 November decision or immediately after it, and revisit only if they move the answer:
a quoted recertification timeline (under $0.1M); quotations against two module and two private-label specifications (under $1.5M); approaches to three private-label buyers and three CGM challengers to establish what work is actually available (under $1M); a cartridge volume study, the one opportunity this analysis did not size (under $1M); and a utilization measurement on the line that would carry medical work (under $0.5M).
Those tests settle the four figures that produce the negative answer, at about a thirteenth of the cost of a first funding stage. Committing $67M before running them buys the same information at thirteen times the price.
- Target
- $350M
- This analysis
- $34.1M
- Target
- above 30%
- This analysis
- -1.7% at 2032
- Met
- No, and the initiative is loss-making throughout
- Target
- above 20%
- This analysis
- -20%, and -26% to -14.8% across the exit-multiple band
- Target
- within 3 years
- This analysis
- Never. Free cash flow is negative in all six years; peak funding $221M
Two things decide this, and neither is execution.
What MERIDIAN could sell is a few percent of what these devices sell for. A printed ECG electrode sells for about $0.30 and its maker is paid about $0.06. The whole world's flexible CGM electrode content is about $92M a year, nearly all made in-house. Priced at what MERIDIAN would be paid rather than at what the devices retail for, everything reachable across every segment sized here comes to about $732M by 2029, and the $350M target is 47.8% of it. No new entrant takes half of everything available in two years of selling.
The tier is less profitable than the one MERIDIAN already occupies. Integer Holdings, the largest listed medical device contract manufacturer, earned an 11.9% operating margin in 2025; Zhen Ding, the closest proxy for the business MERIDIAN wants to leave, earned 7.6%. This initiative reaches -1.7%. Gross margin improves by 6.3 points and the quality, regulatory and sales organization a medical business must carry consumes all of it. The medical premium is real and it sits at the device and reimbursement stages, which the brief rules out.
The motivation for entry is escape from low margins and customer concentration. Medical delivers the second and not the first: at this participation level it is a lower-margin business than the one being escaped, and diversification would cost about $99M of value. That is a legitimate thing to buy and it is not what the four criteria describe. If diversification is the real objective, reset the criteria before November rather than after.
Where the opportunity is, in the order it is worth anything:
- What
- Private-label printed electrodes: return electrodes, ECG and defibrillation pads, ostomy sensor layers
- 2032 revenue
- $117M
- Why
- The printed film is the whole sold unit, so MERIDIAN captures the full price. Commodity work at 22% gross margin against an incumbent specialist, and at $0.06 an ECG electrode it needs about ten roll-to-roll lines
- What
- Single-use electronic modules: on-body injectors, wearable cardiac patches
- 2032 revenue
- $28M
- Why
- Buyers operate no electronics plants, and low-temperature bonding onto PET is the capability MERIDIAN most under-weights. Phillips-Medisize, Nolato and Jabil hold the stage, so only about $51M of the $203M merchant pool is contestable
- What
- Interventional and implantable thin film
- 2032 revenue
- $20M
- Why
- The only tier earning materially above the current business, and the slowest to arrive
- What
- Point-of-care diagnostic cartridges
- 2032 revenue
- not sized here
- Why
- The best capability fit found, and this analysis did not establish a volume for it. Excluded from every total rather than estimated, and the most valuable thing the tests would establish
- What
- Continuous glucose monitoring
- 2032 revenue
- development only
- Why
- Abbott is the largest participant and makes its own; Dexcom's electrode is a patterned wire and cannot be supplied with this technology at all
- What
- Insulin patch-pump pods
- 2032 revenue
- excluded
- Why
- Insulet manufactures the Omnipod itself, which makes the pod one of the most captive items in the set
- What
- Brain-computer interfaces
- 2032 revenue
- research only
- Why
- No implantable BCI holds a therapeutic marketing authorization anywhere
On acquisition: the $35M reference buys about $21M of revenue. It can buy a certificate, a customer list and a quality system, pulling first revenue forward by about a year. It cannot buy the target, and on these economics it buys a faster route into a loss-making position.
Units and terms
The executive summary puts market sizes, device prices, content per unit and margins within a few sentences of each other; this is what each one measures.
- What it means here
- What device makers sell to their customers, at manufacturer revenue. A CGM "market" of $13,662M is what Abbott, Dexcom and others booked, not what patients paid.
- What it means here
- The price MERIDIAN would charge for the part it makes, per device. It is a small fraction of the device price, and it is the number that matters for revenue.
- What it means here
- Content per unit times units. What the whole world spends on that part, whoever makes it.
- What it means here
- The part of the pool that is not made in-house by the company selling the device. Every share in this analysis is computed against this, never against the device market.
- What it means here
- Revenue less materials, direct conversion and allocated plant, as a percentage of revenue.
- What it means here
- Gross profit less the quality, regulatory, engineering and sales organization, as a percentage of revenue. Measured at the initiative, carrying its own costs and an allocated share of shared plant, and excluding corporate overhead the initiative does not cause.
- What it means here
- Calendar 2029. Entry begins 1 January 2027, the first full year after the decision deadline, so the six-year horizon runs 2027 to 2032.
- What it means here
- Chip-on-film. A packaging technology that mounts a driver chip directly onto a flexible film carrying fine circuit traces. MERIDIAN's current product.
- What it means here
- Manufacturing on a continuous web of film rather than sheet by sheet. It is what makes a printed electrode cost cents rather than dollars, and it is MERIDIAN's structural cost advantage.
- What it means here
- How narrow the conductor lines and the gaps between them are. MERIDIAN states approximately 10 micrometers.
- What it means here
- The quality management standard for medical device manufacture. Component and subassembly suppliers are near-universally required to hold it. MERIDIAN's lapsed in December 2021.
- What it means here
- The biological evaluation standard for materials in patient contact. MERIDIAN has completed four of its evaluation items.
- What it means here
- Regulatory risk classes. Class I is lowest risk and Class III covers most implants, with the longest approval path.
- What it means here
- The US clearance route for most Class II devices, based on equivalence to a device already on the market.
- What it means here
- Contract development and manufacturing organization. A company that manufactures for device makers under their brand.
Every figure in this analysis is on one of a small number of bases, and the executive summary above puts several of them within a few sentences of each other. This section says what each one measures.
Section added · The summary states content per unit, device prices, market sizes and margins on four different bases within a few sentences. A reader cannot compose them without a conversion, and an appendix arrives after they have built a picture.